Hua-jay J. Cherng

Hua-jay J. Cherng

Hematology | Oncology
161 Fort Washington Avenue
Floor G
New York, NY 10032

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.

Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.

Journal: Leukemia & lymphoma
Published: June 07, 2026

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.

Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes.

Journal: Haematologica
Published: March 17, 2026

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.

Journal: HemaSphere
Published: November 21, 2025

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Journal: Blood
Published: September 02, 2025

Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.

Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.

Journal: Leukemia & lymphoma
Published: August 14, 2025

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 13, 2025

Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.

Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 26, 2025

Implementing Financial Screening for Adolescents and Young Adults Treated in the Outpatient Oncology Setting.

Implementing Financial Screening for Adolescents and Young Adults Treated in the Outpatient Oncology Setting.

Journal: JCO oncology practice
Published: June 09, 2025

Highlights of American Society of Hematology 2024-lymphoma.

Highlights of American Society of Hematology 2024-lymphoma.

Journal: The oncologist
Published: April 01, 2025

Measurable Residual Disease Testing During Treatment with Bispecific Antibodies for Lymphoma.

Measurable Residual Disease Testing During Treatment with Bispecific Antibodies for Lymphoma.

Journal: Cancers
Published: February 13, 2025

Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia.

Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia.

Journal: Blood neoplasia
Published: January 15, 2025

Retrospective evaluation of R-EPOCH in the frontline treatment of adult patients with PTLD after solid organ transplant.

Retrospective evaluation of R-EPOCH in the frontline treatment of adult patients with PTLD after solid organ transplant.

Journal: Blood neoplasia
Published: December 09, 2024
Showing 1-12 of 27

Last Updated: 09/26/2026